Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs.
Tsukamoto S, Sugi NH, Nishibata K, Nakazawa Y, Ito D, Fukushima S, Nakagawa T, Ichikawa K, Kato Y, Kakiuchi D, Goto A, Itoh-Yagi M, Aota T, Inoue S, Yamane Y, Murai N, Azuma H, Nagao S, Sasai K, Akagi T, Imai T, Matsui J, Matsushima T. Tsukamoto S, et al. Among authors: nakagawa t. Mol Cancer Ther. 2023 Jan 3;22(1):12-24. doi: 10.1158/1535-7163.MCT-21-0879. Mol Cancer Ther. 2023. PMID: 36279567
E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.
Watanabe Miyano S, Yamamoto Y, Kodama K, Miyajima Y, Mikamoto M, Nakagawa T, Kuramochi H, Funasaka S, Nagao S, Sugi NH, Okamoto K, Minoshima Y, Nakatani Y, Karoji Y, Ohashi I, Yamane Y, Okada T, Matsushima T, Matsui J, Iwata M, Uenaka T, Tsuruoka A. Watanabe Miyano S, et al. Among authors: nakagawa t. Mol Cancer Ther. 2016 Nov;15(11):2630-2639. doi: 10.1158/1535-7163.MCT-16-0261. Epub 2016 Aug 17. Mol Cancer Ther. 2016. PMID: 27535969
Discovery of a potent and selective Axl inhibitor in preclinical model.
Inoue S, Yamane Y, Tsukamoto S, Azuma H, Nagao S, Murai N, Nishibata K, Fukushima S, Ichikawa K, Nakagawa T, Hata Sugi N, Ito D, Kato Y, Goto A, Kakiuchi D, Ueno T, Matsui J, Matsushima T. Inoue S, et al. Among authors: nakagawa t. Bioorg Med Chem. 2021 Jun 1;39:116137. doi: 10.1016/j.bmc.2021.116137. Epub 2021 Apr 21. Bioorg Med Chem. 2021. PMID: 33930844
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
Inoue S, Yamane Y, Tsukamoto S, Murai N, Azuma H, Nagao S, Nishibata K, Fukushima S, Ichikawa K, Nakagawa T, Hata Sugi N, Ito D, Kato Y, Goto A, Kakiuchi D, Ueno T, Matsui J, Matsushima T. Inoue S, et al. Among authors: nakagawa t. Bioorg Med Chem Lett. 2021 Sep 15;48:128247. doi: 10.1016/j.bmcl.2021.128247. Epub 2021 Jul 13. Bioorg Med Chem Lett. 2021. PMID: 34271070
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
Taniguchi H, Takeuchi S, Fukuda K, Nakagawa T, Arai S, Nanjo S, Yamada T, Yamaguchi H, Mukae H, Yano S. Taniguchi H, et al. Among authors: nakagawa t. Cancer Sci. 2017 Jan;108(1):53-60. doi: 10.1111/cas.13111. Epub 2016 Dec 30. Cancer Sci. 2017. PMID: 27783866 Free PMC article.
Podoplanin Drives Amoeboid Invasion in Canine and Human Mucosal Melanoma.
Shinada M, Kato D, Motegi T, Tsuboi M, Ikeda N, Aoki S, Iguchi T, Li T, Kodera Y, Ota R, Hashimoto Y, Takahashi Y, Chambers J, Uchida K, Kato Y, Nishimura R, Nakagawa T. Shinada M, et al. Among authors: nakagawa t. Mol Cancer Res. 2023 Nov 1;21(11):1205-1219. doi: 10.1158/1541-7786.MCR-22-0929. Mol Cancer Res. 2023. PMID: 37493578
5,399 results